drugset / Trial / NCT02352545

Montelukast for Postinfectious Cough

NCT02352545

Phase 2 Unknown 200 enrolled Beijing Chao Yang Hospital
RandomizedSingle-groupSingle-blindTreatment

Summary

Cough is a common symptom of respiratory medicine clinic patients, which has complex etiology and wide-ranging. Cough is usually divided into three categories by time: acute cough, subacute cough and chronic cough. Subacute has a 3\~8 weeks course of disease. Its main etiology is postinfectious cough, which is mostly secondary to viral infection.Considering its overexpression in postinfectious patient, Cysteinyl leukotriene (CysLTs) plays a role in gathering eosinophils to respiratory. The level of FENO has a significant correlation with inflammatory airway eosinophils. While CysLTs overexpressed in vivo, the level of FENO may increase. Montelukast, as CysLTs-receptor-1 antagonists, plays a role of controlling airway inflammation and decrease airway high activity by suppressing the biological activity of CysLTs. It is effective in theory to therapy sub-acute cough by Montelukast, to short the course and to relieve cough symptoms as soon as possible. The aim is to research whether FENO can be used as a biomarker to optimized treatment regimen of sub-acute cough.

Timeline

Start
2014-08
Primary completion
2015-08
Completion
2015-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 10 mg Oral

Indications

No indication recorded.